New directions in the treatment of non-small cell lung cancer: An overview

Oncologist

Volumn 6, Issue SUPPL. 1, 2001, Pages 1-3

  Edelman, Martin J ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035129436     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_1-1     Document Type: Conference Paper

References (19)

1. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients
2. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase 11 study
3. The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer
4. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer
5. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer
6. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group study
7. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients
8. A randomised phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
9. An economic analysis of Southwest Oncology Group Trial S9509: Cisplatin/vinorelbine versus carboplatin/paclitaxel for advanced non-small cell lung cancer
10. Carboplatin and vinorelbine in advanced non-small cell lung cancer: A phase I/II study
11. A phase I/II study of vinoreline (NAV) and carboplatin (CARB) for advanced non-small cell lung cancer (NSCLC)
12. Gemcitabine and vinorelbine in advanced non-small cell lung carcinoma: A phase II study
13. Options in advanced non-small cell lung cancer: A review and report on a phase II study of vinorelbine plus gemcitabine
14. A randomised phase III trial of four chemotherapeutic regimens in advanced non-small cell lung cancer (NSCLC)
15. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: A preliminary report of a phase I dose escalation trial from the Carolina Therapy Consortium
16. A randomized phase II study of gemcitabine or paclitael or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB Study 9431)
17. Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer
18. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized trials
19. A randomised trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small cell lung cancer